Taageer Finance Company SAOG (MSM:TFCI)

Regulus Therapeutics Cash Flow Statement

Financials in millions OMR. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Net Income	-	5.53	4.82	3.38	2.54	2.07
Depreciation & Amortization	-	0.37	0.41	0.36	0.44	0.42
Asset Writedown & Restructuring Costs	-	0.32	0.33	0.45	-	-
Provision for Credit Losses	-	6.28	4.67	3.54	2.79	2.02
Change in Accounts Payable	-	1.04	0.05	0.72	-0.5	0.4
Change in Other Net Operating Assets	-	-24.47	-29.17	-20.66	3.41	9.99
Other Operating Activities	-	0.1	0.16	0.13	0.39	-0.26
Operating Cash Flow	-	-10.85	-18.74	-12.1	8.93	14.66
Operating Cash Flow Growth	-	-	-	-	-39.06%	-
Capital Expenditures	-	-0.22	-0.32	-0.45	-0.11	-0.27
Sale of Property, Plant & Equipment	-	0.02	-	0.01	-	-
Other Investing Activities	-	-0.34	8.23	-6.25	-3.8	-
Investing Cash Flow	-	-0.53	7.91	-6.69	-3.91	-0.27
Short-Term Debt Issued	-	56.65	36.3	15.89	14.2	25.63
Long-Term Debt Issued	-	61.63	50.07	63.13	39.6	27.2
Total Debt Issued	-	118.28	86.37	79.02	53.8	52.83
Short-Term Debt Repaid	-	-46.15	-24.15	-36.44	-18.45	-23.3
Long-Term Debt Repaid	-	-50.83	-47.23	-28.72	-29.29	-42.4
Total Debt Repaid	-	-96.98	-71.38	-65.16	-47.74	-65.7
Net Debt Issued (Repaid)	-	21.3	14.99	13.86	6.06	-12.87
Common Dividends Paid	-	-1.85	-1.29	-0.76	-	-2.03
Other Financing Activities	-	-0.31	-	-	-	-1.61
Financing Cash Flow	-	19.15	13.7	13.1	6.06	-16.51
Net Cash Flow	-	7.76	2.87	-5.69	11.09	-2.12
Free Cash Flow	-	-11.07	-19.06	-12.55	8.83	14.39
Free Cash Flow Growth	-	-	-	-	-38.67%	-
Free Cash Flow Margin	-	-83.66%	-160.32%	-129.00%	113.08%	199.79%
Free Cash Flow Per Share	-	-0.04	-0.07	-0.04	0.03	0.05
Cash Interest Paid	-	-	-	-	-	8.38
Cash Income Tax Paid	-	0.86	0.59	0.46	0.37	0.7

Source: S&P Global Market Intelligence. Financial Services template. Financial Sources.